维尔生物技术 VIR

On March 4, 2026, the Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio's Chief Executive Officer and principal executive officer, to the additional position of President. Marianne De Backer, M.Sc., Ph.D., MBA, 56, has served as our Chief Executive Officer and as a member of the Board of Directors since April 2023. From 2019 to March 2023, Dr. De Backer served as a member of the Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing of the Pharmaceuticals division of Bayer AG. Previously, from 1991 to 2019, she was at Johnson & Johnson, a pharmaceutical company, where she most recently held global Business and Corporate Development roles, including the position of Vice President of M&A Operations and Divestitures globally for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development. Prior to that she led a commercial business unit in Europe, as well as drug discovery research in both Europe and the United States. Dr. De Backer currently serves on the board of directors for BIO and as a non-executive director on the board of directors of the Gladstone Foundation, a nonprofit organization. Dr. De Backer previously served on the board of directors of Arrowhead Pharmaceuticals Inc., a U.S. publicly traded biotechnology company, from 2019 to 2023, and the Board of Directors of Kronos Bio, Inc., a U.S. publicly traded biotechnology company, from 2021 to 2023. Dr. De Backer holds a Master in molecular biology from the Vrije Universiteit Brussels, a Master in engineering and biochemistry and a Ph.D. in biotechnology from the Ghent University, Belgium, and an M.B.A. from Erasmus University, Rotterdam.

Vanina de Verneuil, J.D., has served as our Executive Vice President, General Counsel and Corporate Secretary since November 2023. She first joined Vir Bio in 2020 as Vice President, Corporate Law, and in 2022, she took on the Senior Vice President, Corporate Law and Interim General Counsel role, and was then promoted to Senior Vice President, Legal and Corporate Secretary in 2023. Ms. de Verneuil has over two decades of experience representing publicly listed companies and their boards of directors, as well as biopharma investors. Prior to joining Vir Bio, Ms. de Verneuil was a partner at DLA Piper, a leading international law firm with deep roots in the life sciences industry, where she served as outside counsel to publicly listed companies and biopharma investors. Prior to that, she was Global General Counsel at Reliance Communications (Enterprise)/Global Cloud Xchange, a publicly traded global data communications service provider. Ms. de Verneuil received a B.A. in psychology and French from Duke University, and a J.D. from New York University School of Law.

Elliott Sigal, M.D., Ph.D., has served as a member of the Board of Directors since July 2020. Dr. Sigal currently serves as a senior advisor to select biopharmaceutical companies. Previously, he served as Chief Scientific Officer and President of Research & Development of BMS from 2004 until his retirement in 2013 and served on the board of directors from 2011 to 2013. Dr. Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from 2001 to 2013. Prior to BMS, he was Vice President of R&D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. Dr. Sigal currently serves on the board of directors of Alnylam Pharmaceuticals, Inc., a U.S. publicly traded biotechnology company, since 2022. He previously served on the boards of directors of several U.S. publicly traded companies in addition to BMS, including: Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, from 2014 to 2023; Surface Oncology, Inc., an immuno-oncology company, from 2018 to 2023; Spark Therapeutics, Inc., a commercial-stage gene therapy company, from 2014 to 2018; and Mead Johnson Nutrition Company, a global pediatric nutrition company, from 2009 to 2017. Dr. Sigal also serves on the boards of directors of several private biotechnology companies, including: Affinia Therapeutics Inc., a preclinical stage gene therapy company, since 2020; and Tessera Therapeutics, a genome engineering company, since 2021. In addition, he co-chairs the Scientific Advisory Board for Amgen Inc., a U.S. publicly traded biopharmaceutical company. Dr. Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an M.D. from the University of Chicago. He completed his training in internal medicine and pulmonary medicine at University of California, San Francisco School of Medicine, where he also received his research training at the Cardiovascular Research Institute and later served on the faculty. Chief Scientific Officer and President of Research & Development, Bristol-Myers Squibb Company (2004 - 2013), and preceded by various positions of increasing responsibility (1997 - 2004). President and Chief Executive Officer, Mercator Genetics Inc. (1996 - 1997), and previously Vice President of Research and Development (1995 - 1996). B.S., M.S. and Ph.D., Industrial Engineering, Purdue University, M.D., University of Chicago.

Jeffrey S. Hatfield, has served as a member of the Board of Directors since December 2020. Since 2023, Mr. Hatfield has served as Chairman of Vividion Therapeutics, Inc. (Vividion), a private biotechnology company that was acquired in 2021 as an arm's length subsidiary within the Pharmaceuticals division of Bayer AG, a multinational pharmaceutical and biotechnology company. He previously served as Vividion's Chief Executive Officer from 2020 to 2023. Mr. Hatfield has also served as Chairman of ROME Therapeutics, Inc., a private biotechnology company, since 2022, and as a member of the board of directors of Gate Bioscience, Inc., a private biotechnology company, since August 2024. Previously, he served as Chief Executive Officer and board member of Zafgen, Inc. (Zafgen), a U.S. publicly traded biopharmaceutical company, from 2017 until its acquisition of, and name change to, Larimar Therapeutics, Inc. in 2020, and as President, Chief Executive Officer and board member of Vitae Pharmaceuticals, Inc. (Vitae), a U.S. publicly traded clinical-stage biotechnology company, from 2004 until its acquisition by Allergan plc in 2016. Prior to working at Vitae, Mr. Hatfield served in numerous executive capacities at Bristol-Myers Squibb Company (BMS), including Senior Vice President of BMS' Immunology and Virology divisions, President and General Manager of BMS Canada and Head of U.S. Market Access. In addition to Zafgen and Vitae, Mr. Hatfield has previously served on the boards of directors of several publicly traded biotechnology companies, including: MiRagen Therapeutics, Inc. (Chairman), from 2017 to 2021 (including its acquisition of, and name change to, Viridian Therapeutics in 2020); aTyr Pharma, Inc., from 2017 to 2021; Ambit Biosciences Corp., during 2014 (prior to its acquisition by Daiichi Sankyo Company, Ltd.); and InVivo Therapeutics, Inc., from 2016 to 2018. Mr. Hatfield is also a Key Advisory Board member for the Harvard Business School's Blavatnik Fellowship in Life Sciences Entrepreneurship. Mr. Hatfield holds a B.S. in pharmacy from Purdue University's College of Pharmacy and an M.B.A. from The Wharton School at the University of Pennsylvania.

Robert More, has served as a member of the Board of Directors since September 2016. Since 2016, Mr. More has served as Managing Director of Alta Partners, a venture capital firm. From 2013 to 2015, he served as Senior Advisor for the Bill & Melinda Gates Foundation, a private foundation that supports initiatives in education, world health and reducing poverty, and led its Global Health Venture Initiative. He served as a General Partner of venture capital firms Frazier Healthcare Ventures and Domain Associates from 2008 to 2013 and from 1996 to 2008, respectively. Mr. More has served on the board of directors of Tyra Biosciences, Inc., a U.S. publicly traded biotechnology company, since 2018 (and as its Chairman since 2019). He also currently serves on the boards of directors of the following private biotechnology companies: Amplitude Therapeutics, Inc.; eGenesis, Inc.; Kelonia Therapeutics, Inc.; MBrace Therapeutics, Inc.; Variant Bio, Inc.; and as an advisor for LiquiGlide, Inc. Mr. More previously served on the boards of directors of the following U.S. publicly traded companies: Achaogen, Inc., a biopharmaceutical company; Neothetics Inc., a pharmaceutical company; Glaukos Corporation, a medical technology company; IntraLase Corp., a medical device company (acquired by Advanced Medical Optics in 2007); and Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company. He also previously served on the boards of directors of the following private life sciences companies: Affinivax, Inc. (acquired by GSK plc in 2022); Hangzhou Qihan Biotech Co., Ltd.; Sirenas, LLC; Carticept Medical, Inc.; Cartiva, Inc.; ESP Pharma, Inc.; Proxima Therapeutics, Inc.; NovaCardia, Inc.; Esprit Pharma, Inc.; and Oceana Therapeutics, Inc. Mr. More was a founding member of the board of directors of the Kauffman Fellows Program and previously served on the boards of directors of One Revolution and The Foundation for Innovative New Diagnostics (FIND). In addition, Mr. More previously served on one of the governing boards of the Biotechnology Innovation Organization (BIO). He received his B.S. in Biology from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.

Saira Ramasastry, has served as a member of the Board of Directors since September 2019. Since 2009, Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life sciences industry. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc., an investment management company, where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch, she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from 1997 to 1998. Ms. Ramasastry currently serves on the boards of directors of Day One Biopharmaceuticals, Inc., since 2021, and Mirum Pharmaceuticals, Inc., since 2022, each a U.S. publicly traded biotechnology company, as well as Glenmark Pharmaceuticals, Ltd., a BSE and NSE-traded pharmaceuticals company, since 2019. She previously served on the boards of directors of several U.S. publicly traded companies, including: Innovate Biopharmaceuticals, Inc., a biotechnology company, from 2018 until its merger with RDD Pharma Ltd. in 2020; Repros Therapeutics Inc., a biopharmaceutical company, from 2013 until it was acquired by Allergan plc in 2018; Cassava Sciences, Inc., a biopharmaceutical company, from 2013 to 2020; Sangamo Therapeutics, Inc., a biotechnology company, from 2012 to 2022; and Akouos, Inc., a biotechnology company, from 2020 until it was acquired by Eli Lilly and Company in 2022. Ms. Ramasastry received her B.A. in economics with honors and distinction and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge, where she is also a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.

Norbert Bischofberger, Ph.D., has served as a member of the Board of Directors since May 2024. Dr. Bischofberger served as President and Chief Executive Officer of Kronos Bio, Inc., a U.S. publicly traded biotechnology company, from 2018 to December 2024, and he continues to serve as a member of the Kronos Bio board of directors. Prior to joining Kronos Bio, Dr. Bischofberger was the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead Sciences, Inc. Dr. Bischofberger joined Gilead in 1990 as Director of Chemistry after having worked as a Senior Scientist in Genentech, Inc.'s DNA Synthesis Group from 1986 to 1990. During his 28-year tenure at Gilead, Dr. Bischofberger presided over the development and approval of more than 25 medicines for a range of serious conditions which led to the transformation of the treatment of diseases such as HIV and viral hepatitis, including hepatitis B and hepatitis C. Dr. Bischofberger was part of the core management team that grew Gilead from less than 50 employees with no revenue to 10,000 employees with $25 billion in revenue. Dr. Bischofberger received a Ph.D. in organic chemistry from Zurich's Eidgenossische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside's lab at Harvard University in Cambridge, Massachusetts. Dr. Bischofberger received an honorary doctorate in Natural Sciences (2016) from The University of Innsbruck and an honorary doctorate in Letters in Medicine (2017) from Baylor College of Medicine and was also elected a Fellow of The American Association for Advancement of Science (2018). In addition to his roles at Vir Bio and Kronos Bio, Dr. Bischofberger also serves on the boards of directors of MiNA Therapeutics Limited, a private biotechnology company focused on small activating RNA therapeutics, since March 2025, and Rezo Therapeutics, Inc., a private biotechnology company focused on mapping disease networks, since 2021. He previously served on the board of directors of Morphic Therapeutic Inc., a U.S. publicly traded biopharmaceutical company, from 2019 until it was acquired by Eli Lilly and Company in August 2024, and the Supervisory Board of Bayer AG, from 2017 to April 2024.

Ramy Farid, Ph.D., has served as a member of the Board of Directors since May 2024. Dr. Farid currently serves as President and Chief Executive Officer, and as a member of the Board of Directors, of Schrodinger, Inc., a U.S. publicly traded biotechnology company. He joined Schrodinger in 2002 and helped advance the company's computational platform and drug discovery portfolio while assuming positions of increasing responsibility before becoming a member of the Board of Directors in 2012 and Chief Executive Officer in 2017. Dr. Farid has played a key role in implementing major strategic initiatives at Schrodinger, including more than 40 research collaborations and joint ventures, and led the company through its initial public offering in 2020. Dr. Farid currently serves on the board of directors of Ajax Therapeutics, Inc., a private biotechnology company (and collaboration partner of Schrodinger), since 2019, and previously served on the boards of directors of other U.S. publicly traded biotechnology and biopharmaceutical companies, including: Structure Therapeutics Inc., from 2019 to June 2024; and Morphic Therapeutic Inc., from 2016 to 2019 (later acquired by Eli Lilly and Company in August 2024). He also previously served on the boards of directors of several private biotechnology companies, including: Nimbus Therapeutics (which he helped found), from 2009 to 2020; and Oak Hill Bio Ltd., from 2022 to 2024. Dr. Farid began his career in academia and was an assistant professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his doctorate degree in chemistry from Caltech. He is an author on over 100 peer reviewed publications.

Janet Napolitano, J.D., has served as a member of the Board of Directors since August 2020. Ms. Napolitano currently serves as Professor of Public Policy at the Goldman School of Public Policy and is the Founder and Faculty Director of the Center for Security in Politics, each at the University of California, Berkeley. Previously, she served as the 20th President of the University of California from 2013 to 2020 and was first appointed as a tenured faculty member at the Goldman School of Public Policy in 2014. Prior to her time serving as the President of the University of California, she served as the U.S. Secretary of Homeland Security from 2009 to 2013, as Governor of the state of Arizona from 2003 to 2009, as Attorney General of Arizona from 1998 to 2003 and as U.S. Attorney for the District of Arizona from 1993 to 1997. In 2010, Ms. Napolitano was awarded the University of Virginia's Thomas Jefferson Foundation Medal for law. In 2015, Ms. Napolitano was elected to the American Academy of Arts and Sciences, and in 2017, she was inducted into the American Philosophical Association. Ms. Napolitano currently serves on the Council of the American Law Institute and has served on the boards of directors of Zoom Video Communications, Inc., a U.S. publicly traded communications technology company, since 2020, Fortinet, Inc., a U.S. publicly traded cybersecurity and networking solutions company, since November 2024, as well as on the Council on Foreign Relations and the board of trustees at RAND Corporation. Ms. Napolitano holds a B.S. in political science (summa cum laude) from Santa Clara University, where she was a Truman Scholar and the university's first female valedictorian, and a J.D. from the University of Virginia School of Law.

On July 23, 2026, the Board of Directors of Vir Bio appointed Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer of Vir Bio, as interim Principal Financial Officer of Vir Bio, effective August 3, 2026. Mr. Sabatini has served as the Senior Vice President and Chief Accounting Officer of Vir Bio since February 2023 and as the principal accounting officer of Vir Bio since October 2024. He has more than two decades of relevant experience; previously, from March 2021 to February 2023, he was at Capsida Biotherapeutics, Inc., most recently as Head of Finance. Prior to that, Mr. Sabatini was at Amgen Inc. from April 2004 to March 2021 where he progressed through various positions of increasing responsibility, including leadership roles in Accounting, Tax and Financial Planning and Analysis. Mr. Sabatini is a Certified Public Accountant and received a B.S. in Accountancy from California State University, Northridge and an MBA from the University of Michigan's Stephen M. Ross School of Business. Effective as of October 5, 2026, Brent Sabatini, CPA, MBA, will cease serving as the Company's interim principal financial officer and continue in his role as Senior Vice President and Chief Accounting Officer and principal accounting officer of the Company.

On October 1, 2026, Vir Biotechnology, Inc. announced that Aziz Sawaf, MBEE, MBA, CFA has been appointed as Executive Vice President and Chief Financial Officer and principal financial officer of the Company, effective as of October 5, 2026. Mr. Sawaf, served as Chief Financial Officer since 2023 and also Senior Vice President of Operations Strategy since 2025 at Theravance Biopharma, Inc. (Theravance). He first joined Theravance in 2014, holding financial leadership roles of increasing responsibility before being appointed Chief Financial Officer. Prior to Theravance, Mr. Sawaf held roles on the R&D and commercial finance teams at Gilead Sciences, Inc. He received a B.S. in Business Administration from the University of Arizona, an MBA from the University of Southern California, Marshall School of Business and an MBEE from Johns Hopkins University. Mr. Sawaf is also a CFA charterholder.

On June 9, 2026, the Board of Directors of Vir Biotechnology, Inc. appointed Timothy Coughlin, CPA, to serve on the Board as a Class III director. Mr. Coughlin is the former Chief Financial Officer of Neurocrine Biosciences, Inc., where he helped lead the company's transition from a clinical-stage biotechnology company to a fully integrated commercial pharmaceutical company, rebuilding after a key regulatory setback and bringing important therapies to patients while at the same time increasing shareholder value. Prior to joining Neurocrine, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as Vice President, Financial Services. Earlier in his career, Mr. Coughlin served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors. Mr. Coughlin currently serves as chair of the board of directors of aTyr Pharma, Inc. and as a member of the boards of directors of ADC Therapeutics SA and Travere Therapeutics, Inc. He previously served on the boards of directors of Fate Therapeutics, Inc. and Peloton Therapeutics, Inc. prior to its sale to Merck in 2019. Mr. Coughlin holds a master's degree in international business from San Diego State University and a bachelor's degree in accounting from Temple University. He is a certified public accountant in both California and Pennsylvania.